| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||
1,411 | 1,411 | 654 | 456 | - | - | - | - | - | - |
Cost of goods sold | |||||||||
531 | 415 | 148 | 181 | - | - | - | - | - | - |
Revenue | |||||||||
- | - | - | - | 654 | 951 | 468 | 188 | 96 | 0 |
Cost of goods sold | |||||||||
- | - | - | - | 303 | 385 | 189 | 128 | 56 | 0 |
Gross margin | |||||||||
879 | 995 | 506 | 274 | 350 | 566 | 278 | 60 | 40 | 0 |
General and administrative expense | |||||||||
9,781 | 4,626 | 4,050 | 5,174 | 3,399 | 4,882 | 7,530 | 6,285 | 3,561 | 1,874 |
Operations expense | |||||||||
2,960 | 1,861 | 1,414 | 1,158 | 846 | 972 | 1,096 | 761 | 351 | 276 |
Sales and marketing expense | |||||||||
1,912 | 2,369 | 1,095 | 467 | 503 | 1,178 | 578 | 172 | 232 | 199 |
Total operating loss | |||||||||
-13,774 | -7,861 | - | - | - | - | - | - | - | - |
Gain on revaluation of cash advances to Helomics | |||||||||
1,222 | - | - | - | - | - | - | - | - | - |
Total operating loss | |||||||||
- | - | 6,053 | - | - | - | - | - | - | - |
Other income | |||||||||
287 | 510 | 53 | - | - | - | - | - | - | - |
Other expense | |||||||||
3,979 | 441 | 3 | - | - | - | - | - | - | - |
Impairment | |||||||||
8,100 | 0 | - | - | - | - | - | - | - | - |
Loss on intangible impairment | |||||||||
770 | - | - | - | - | - | - | - | - | - |
Interest expense | |||||||||
- | - | - | - | 390 | 377 | 636 | 259 | 230 | 147 |
Loss (gain) on valuation of equity-linked financial instruments | |||||||||
- | - | - | - | - | 11 | 157 | -3 | -151 | 1,145 |
Total Expense | |||||||||
- | - | - | 6,800 | 5,140 | 7,399 | - | - | - | - |
Loss on equity method investment | |||||||||
-439 | -2,293 | - | - | - | - | - | - | - | - |
Gain on revaluation of equity method investment | |||||||||
6,164 | - | - | - | - | - | - | - | - | - |
Net loss | |||||||||
-19,390 | -10,086 | - | - | - | - | - | - | - | - |
Deemed dividend on Series E Convertible Preferred Stock | |||||||||
289 | - | - | - | - | - | - | - | - | - |
Total Expense | |||||||||
- | - | - | 6,800 | - | - | - | - | - | - |
Total expense | |||||||||
- | - | - | - | - | - | 9,684 | 7,482 | 4,527 | 1,352 |
Net loss attributable to common shareholders | |||||||||
-19,680 | -10,086 | -6,003 | -6,526 | -4,790 | -6,833 | -9,406 | -7,422 | -4,486 | -1,352 |
Unrealized gain from marketable securities | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Comprehensive loss | |||||||||
- | - | - | -6,524 | -4,790 | - | - | - | - | - |
Loss per common share - basic and diluted (in dollars per share) | |||||||||
-6.86 | -7.87 | -0.94 | -2.31 | -30.86 | -57.13 | -4.64 | -0.11 | -0.18 | -0.11 |
Weighted average shares used in computation - basic and diluted (in shares) | |||||||||
2,870 | 1,281 | 6,362 | 2,823 | 155 | 119 | 2,026 | 69,587 | 24,282 | - |
Weighted average shares used in computation - basic and diluted (in shares) | |||||||||
- | - | - | - | - | - | - | - | - | 12,771 |